Loading...
XNASACIU
Market cap267mUSD
Dec 23, Last price  
2.68USD
1D
0.00%
1Q
-27.96%
Jan 2017
-79.35%
IPO
-83.76%
Name

AC Immune SA

Chart & Performance

D1W1MN
XNAS:ACIU chart
P/E
P/S
16.26
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
6.49%
Rev. gr., 5y
15.52%
Revenues
15m
+276.14%
8,637,00030,269,00039,090,00023,214,00020,255,0007,194,000111,026,00015,431,00003,935,00014,801,000
Net income
-54m
L-23.35%
-11,243,00010,744,00020,270,000-7,096,000-26,411,000-50,951,00045,442,000-62,105,000-72,996,000-70,753,000-54,233,000
CFO
-60m
L-17.89%
-19,804,000-17,624,00044,084,000-5,646,000-22,094,000-44,078,00055,220,000-59,517,000-65,689,000-73,568,000-60,408,000
Earnings
Mar 12, 2025

Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
IPO date
Sep 23, 2016
Employees
126
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
14,801
276.14%
3,935
 
Cost of revenue
119,788
136,461
135,443
Unusual Expense (Income)
NOPBT
(104,987)
(132,526)
(135,443)
NOPBT Margin
Operating Taxes
10
13
3
Tax Rate
NOPAT
(104,997)
(132,539)
(135,446)
Net income
(54,233)
-23.35%
(70,753)
-3.07%
(72,996)
17.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,798
(1,000)
16,720
BB yield
-10.34%
0.00%
-4.51%
Debt
Debt current
672
548
570
Long-term debt
6,322
5,054
5,250
Deferred revenue
Other long-term liabilities
5,770
3,213
7,098
Net debt
(96,415)
(117,345)
(192,759)
Cash flow
Cash from operating activities
(60,408)
(73,568)
(65,689)
CAPEX
(801)
(1,239)
(2,635)
Cash from investing activities
65,645
23,763
(53,664)
Cash from financing activities
43,250
(1,346)
40,746
FCF
(114,015)
(131,576)
(136,837)
Balance
Cash
103,048
122,586
198,216
Long term investments
361
361
363
Excess cash
102,669
122,750
198,579
Stockholders' equity
(314,159)
(262,208)
(199,148)
Invested Capital
484,069
437,213
441,135
ROIC
ROCE
EV
Common stock shares outstanding
84,695
83,554
74,952
Price
5.00
145.10%
2.04
-58.79%
4.95
-4.26%
Market cap
423,473
148.44%
170,451
-54.06%
371,012
-0.19%
EV
327,058
53,106
178,253
EBITDA
(102,772)
(130,167)
(133,037)
EV/EBITDA
Interest
176
355
581
Interest/NOPBT